Skip to main content

Table 1 Demographic Characteristics

From: Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration

  Full Analysis Set
(n = 185)
Per-Protocol Set
(n = 125)
Characteristic at baseline
 Age, years 77.6 (8.5) 78.2 (8.0)
 Female, n (%) 109 (58.9) 79 (63.2)
 Duration of nAMD, months 8.5 (7.3) 7.4 (3.3)
Characteristic before any treatment, including ranibizumab
 BCVA, ETDRS letters 62.4 (16.6)a 64.0 (15.6)
 CRT, μm 368.3 (124.4)b 362.4 (115.2)c
 Subretinal fluid, n (%) 133 (76.9)b 92 (74.2)c
 Intraretinal fluid, n (%) 76 (43.9)b 55 (44.4)c
 Pigment epithelium detachment, n (%) 125 (72.3)b 88 (71.0)c
  1. Mean (standard deviation) unless otherwise stated
  2. an = 163; bn = 161; cn = 116; values correspond to assessments before any treatment, including ranibizumab, had been administered
  3. BCVA Best-corrected visual acuity, CRT Central retinal thickness, ETDRS Early Treatment Diabetic Retinopathy Study, nAMD Neovascular age-related macular degeneration
\